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Response to therapeutic sleep deprivation: a naturalistic study
of clinical and genetic factors and post-treatment depressive
symptom trajectory
Nina Trautmann1,2, Jerome C. Foo1, Josef Frank 1, Stephanie H. Witt 1, Fabian Streit 1, Jens Treutlein1,
Steffen Conrad von Heydendorff2, Maria Gilles2, Andreas J. Forstner 3,4,5,6,7, Ulrich Ebner-Priemer8, Markus M. Nöthen3,4,
Michael Deuschle2 and Marcella Rietschel 1 Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
Research has shown that therapeutic sleep deprivation (SD) has rapid antidepressant effects in the majority of depressed patients.
Investigation of factors preceding and accompanying these effects may facilitate the identiﬁcation of the underlying biological
mechanisms. This exploratory study aimed to examine clinical and genetic factors predicting response to SD and determine the
impact of SD on illness course. Mood during SD was also assessed via visual analogue scale. Depressed inpatients (n= 78) and
healthy controls (n= 15) underwent ~36 h of SD. Response to SD was deﬁned as a score of ≤ 2 on the Clinical Global Impression
Scale for Global Improvement. Depressive symptom trajectories were evaluated for up to a month using self/expert ratings. Impact
of genetic burden was calculated using polygenic risk scores for major depressive disorder. In total, 72% of patients responded to
SD. Responders and non-responders did not differ in baseline self/expert depression symptom ratings, but mood differed. Response
was associated with lower age (p= 0.007) and later age at life-time disease onset (p= 0.003). Higher genetic burden of depression
was observed in non-responders than healthy controls. Up to a month post SD, depressive symptoms decreased in both patients
groups, but more in responders, in whom effects were sustained. The present ﬁndings suggest that re-examining SD with a greater
focus on biological mechanisms will lead to better understanding of mechanisms of depression.
Neuropsychopharmacology (2018) 43:2572–2577; https://doi.org/10.1038/s41386-018-0092-y
INTRODUCTION
Therapeutic sleep deprivation (SD) reliably induces rapid and
substantial antidepressant effects in the majority of patients with a
major depressive episode [1–4]. A recent meta-analysis of SD
studies showed an average response rate of ~ 50% with signiﬁcant
variability, with up to 78% of patients responding to SD treatment
[5]. Although its therapeutic value is limited due to relapse after
recovery sleep [2, 6], it has been shown that chronotherapeutic
techniques (i.e., sleep phase advance, bright light therapy)
affecting circadian machinery can prolong SD effects [7].
SD is particularly unique in its deﬁned immediate positive effect
on depressive mood and may therefore offer unique insights
about the biological factors underlying depression. Response to
SD has been associated with various factors, including circadian
rhythms [8–11]; tiredness [12]; disease diagnosis and “endogenous
depression” [13–16]; age-related features [17–20], and candidate
gene variants [4, 21, 22]. Several plausible hypotheses have been
formulated [7, 23–25], but a comprehensive understanding of
underlying factors, especially with respect to the biological
mechanisms involved, has not yet been achieved.
MDD is a heterogeneous disorder, and it is thought that a
multitude of genetic variants are involved in course, development,
and response to treatment [26, 27]. Understanding the role of
genetic risk in modulation of response to treatment might allow
the identiﬁcation of potential responders, eventually leading to
improvements in personalized care. It has been observed that
higher genetic burden for psychiatric disorders is associated with
response to treatment [28–30].
Recent genome-wide association studies with large samples
have made substantial progress with identiﬁcation of common
risk variants for MDD [31, 32]. Furthermore, polygenic risk scores
(PRS), which summarize the effects of many single-nucleotide
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polymorphisms in a single risk score offer the ability to associate
burden of disease with clinical and phenotypic factors, and have
been successfully applied to explore the genetic architecture of
complex disorders [29, 31–34].
In this naturalistic exploratory study, we assessed clinical and
genetic factors associated with response to SD, going beyond the
study of individual candidate genes for the ﬁrst time, using all-
genomic information in the form of PRS. We also evaluated mood
longitudinally during SD, and the impact of SD on the further
trajectory of depressive symptoms.
MATERIALS AND METHODS
Participants
Seventy-eight inpatients (34 females; age mean ± standard
deviation= 43.54 ± 14.80 years) presenting with an episode of
major depression (unipolar, n= 71; bipolar I, n= 6; and bipolar
II, n= 1) participated in this study. Depression was diagnosed
according to ICD-10 criteria. Patients were recruited between
August 2013 and April 2015 from consecutive admissions to the
depression unit of the Central Institute of Mental Health (CIMH)
in Mannheim, Germany. The study protocol stipulated that for 5
+ days prior to SD, no changes were allowed to the medication
regimen. Prescribed medication included typical and atypical
antidepressants, lithium, and adjunct therapies (for details,
see supplementary text). Fifteen healthy controls (eight females;
40.53 ± 15.90 years) with no history of psychiatric/somatic
disorders were recruited through an online advertisement on
the CIMH website. The investigation was carried out in
accordance with the latest version of the Declaration of Helsinki
and approved by the local ethics committee. All participants
provided written informed consent following a detailed
explanation of the study.
SD
Participation began on Day 1 (see Fig. 1) whereupon baseline
variables (see below) were assessed. During Day 2, patients
engaged in normal ward routines. SD was conducted in small
groups of 1–5 participants under staff supervision. Participants
remained awake from ~ 0600 h on Day 2 to 1800 h on Day 3 (36 h).
On Day 3, patients engaged in normal ward routines until
undergoing recovery sleep from 1800–0100 h. Sleep phase
advance was then carried out, shifting sleep 1h forward each
day until the patient’s regular sleep pattern was reached. Controls
underwent SD alongside patients; their participation ended after
the ﬁrst recovery sleep.
Data collection
Blood sampling. On Day 1, a venous blood sample was collected
from participants for genome-wide genotyping, which was
performed using the Global Screening Array (Illumina, Inc., San
Diego, CA, USA). Genotyping and quality control procedures are
described in detail in the supplement and elsewhere [29, 33].
Demographic and clinical characteristics. Day 1 assessments
included: demographics, including sex, age, age at initial disease
onset (AaO); clinical parameters (body mass index, pulse); history
of psychiatric and somatic disorders and family history (FH) of
MDD or bipolar disorder (BD).
The validated German version [35] of the Morningness-
Eveningness-Questionnaire (D-MEQ) [36] was used to assess
circadian rhythm/diurnal variation. The D-MEQ comprises 19 items
on circadian patterns, identifying morning, intermediate, and
evening chronotypes.
Response to SD. Response to SD was evaluated between 1600 h
and 1700 h on Day 3 by the senior clinical researcher (MD) using
the Clinical Global Impression Scale for Global Improvement
(CGIC) [37]. Possible CGIC scores were: 1= Very much improved; 2
=Much improved; 3=Minimally improved; 4= No change; 5=
Minimally worse; 6=Much worse; 7= Very much worse. Response
and non-response were deﬁned as scores of ≤ 2 and ≥ 3,
respectively. The CGIC was chosen as the primary response
outcome owing to its utility in measuring immediate response
(see supplementary text for details regarding scale choice).
Depressive Symptoms Scales. The 10-item Montgomery-Åsberg
Depression Rating Scale (MADRS) [38] was completed by the
senior clinical researcher (MD) on Days 1, 4, 10, 17, and 30. The 21-
item Beck Depression Inventory-II (BDI-II) [39] was completed by
patients on Days 1, 3, 10, 17, and 30.
During SD. Participants completed visual analogue scales (VAS)
[40] for mood every 2 h from 1000 h on Day 2–1800 h on Day 3.
Ratings ranged from: “worst mood imaginable (0)” to “best mood
imaginable (10)”. Tiredness ratings were also assessed by VAS
(see supplementary text). Locomotor activity was acquired using
the SOMNOwatch (SOMNOmedics GmbH, Germany), and patients
recorded in a wear log when the device was worn/removed; these
were inspected to identify subjects who had fallen asleep before
response assessment.
Data analysis
Statistical analyses were performed using IBM SPSS Statistics for
Windows version 24. Statistical signiﬁcance was set at p < 0.05.
Descriptive statistics. Descriptive statistics were calculated. For
continuous variables, mean values were compared using inde-
pendent samples t tests. For nominal values, proportions were
compared using Fisher’s exact test.
Genotyping and PRS calculation. PRS [34] were calculated using
genome-wide association data from the Psychiatric Genomics
Consortium MDDII (Cases: n= 59,851, Controls: n= 113,154) [32].
A p value threshold of 1.0 was found to give best-ﬁt (for details,
see supplementary text). Scores were standardized to the mean
and standard deviation of controls [41]. Binomial logistic
Day 1 Day 2 Day 3 Day 4 Day 10 Day 17 Day 31 
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BDI-II 
MADRS MADRS 
Recovery  
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Fig. 1 Schematic timeline of study schedule. CGI= Clinical Global Impression; BDI-II= Beck Depression Inventory-II; MADRS=Montgomery-
Åsberg Depression Rating Scale
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regression was used to compare PRS across disease state. To
compare PRS across groups (non-responder/responder/control)
one-way analysis of variance (ANOVA) was used.
Baseline predictors of response to SD. To identify baseline
predictors of response to SD, a binomial logistic regression
analysis was performed. Response was speciﬁed as the dependent
variable. Categorical independent variables comprised: sex;
diurnal variation (morning/intermediate/evening chronotype);
season (spring/summer/autumn/winter); diagnosis (Unipolar
MDD/BD); and FH. Continuous independent variables comprised:
MDD-PRS; age; AaO; and baseline BDI-II and MADRS scores.
Mood and tiredness trajectories. To compare mood trajectories
between responders and non-responders during SD, a random-
intercepts mixed model was used (accounting for intra-individual
clustering of observations). Mood was speciﬁed as the dependent
variable. MDD-PRS, response, timepoint and the interaction
between response × timepoint were speciﬁed as ﬁxed factors.
Timepoint was centred to midnight and included in a repeated
term with an AR1 covariance structure. The same model with
tiredness as the dependent variable was speciﬁed.
We also tested whether baseline (one-way ANOVA) and mood
trajectories (random-intercepts mixed model, ﬁxed effects: diag-
nosis, timepoint, diagnosis × timepoint interaction) differed
between bipolar and unipolar patients.
Depressive symptoms score trajectories. Correlations between
MADRS and BDI-II scores were examined over all measurement
days. Score trajectories were examined using random-intercepts
mixed models. Fixed effects included sex, season, diagnosis,
response, and measurement day entered as factors. Age, AaO, and
MDD-PRS were entered as covariates. The response ×measure-
ment day interaction was entered as a ﬁxed effect. Measurement
day was included in a repeated term with a diagonal covariance
structure.
RESULTS
Demographics and descriptive statistics
Descriptive statistics are shown in Table S1. Six patients were
excluded from the analysis as they did not complete SD. Four
patients were excluded for having fallen asleep prior to response
rating. Thus, data from a total of 68 patients were included in the
subsequent analyses (except for PRS analysis). A total of 49 (49/68;
72.1%) responded to SD. In total, 5/7 of the bipolar patients
responded to SD.
PRS
The regression model comparing PRS for disease state (controls n
= 15; patients n= 72) found higher PRS in patients at the trend
level (p= 0.068, ΔNagelkerkeR
2= 0.066). The ANOVA to compare
groups (responders n= 46, non-responders n= 18, controls n=
15) found a signiﬁcant difference between groups (F2,76= 3.426, p
= 0.038). A post hoc Tukey test found the group difference to be
driven by higher scores in non-responders than controls
(signiﬁcant, p= 0.029). Although not signiﬁcant, higher scores
were found in non-responders than responders (p= 0.212) and
controls than responders (p= 0.309) (see Fig. 2 and supplemen-
tary text for additional details).
Baseline predictors of response to SD
The regression model included 57 patients due to missing
(assessment or genetic) data (Table S2). The model was statistically
signiﬁcant, χ2(13)= 24.477, p= 0.027, explaining 50.2% of the
variance in response. Lower age (p= .007) and higher AaO (p=
0.003) were signiﬁcantly associated with an increased likelihood of
response. No signiﬁcant effects were found for PRS (p= 0.907); FH
(p= 0.125); sex (p= 0.148); season (p= 0.587); baseline BDI-II
Fig. 2 Polygenic Risk Scores (PRS) for major depression in non-
responders, responders and healthy controls. Scores are standar-
dized to mean and standard deviation of healthy controls. Error bars
denote standard error of mean. * p < 0.05
Fig. 3 Trajectories of mean mood during sleep deprivation. Error
bars denote 95% conﬁdence intervals.
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score (p= 0.986); baseline MADRS score (p= 0.314); diagnosis (p
= 0.691); or diurnal variation (p= 0.343).
Mood and tiredness
Figure 3 shows trajectories for group mean mood throughout SD.
In the mixed model analysis of mood (Table S3a), signiﬁcant main
effects of timepoint (F16,540.801= 2.518, p= 0.001) and response
(F1,63.217= 8.811, p= 0.004) were observed. In the whole cohort,
mood improved over time (see Table S3a), whereas worse mood
was observed in non-responders vs. responders (t= –2.109, df=
215.848, p= 0.036). No signiﬁcant effects of response × timepoint
interaction were observed (p= 0.781; only at the ﬁnal observation
point did the interaction show a trend towards signiﬁcance, p=
0.098). No signiﬁcant effect of MDD-PRS was observed (p= 0.276).
Estimated correlation between any two consecutive assessment
points was signiﬁcant (AR1 rho, p < 0.001).
No signiﬁcant difference was found in baseline mood between
bipolar and unipolar patients (uneven sample sizes, Levene’s
statistic: F1,62= 3.42, p= 0.069; Welch’s Statistic: F1,6.421= 0.366,
p= 0.566). The mixed model found a signiﬁcant main effect of
timepoint (F16,539.414= 1.900, p= 0.018) but not diagnosis
(F1,63.578= 0.23, p= 0.880) or diagnosis × timepoint interaction
(F16,539.414= 0.831, p= 0.651).
The analysis of tiredness (Table S3b) found only a signiﬁcant
effect of timepoint; (F16,544.059= 11.662, p < 0.001) participants
became increasingly tired as time progressed (see supplementary
text for details).
Depressive symptoms (MADRS and BDI-II)
Responders and non-responders did not differ in terms of baseline
MADRS and BDI-II scores (Fig. 4a, b). The correlation between
MADRS and BDI-II scores on all measurement days was consistent
(all Pearson r ≥ 0.4) and signiﬁcant (all p < 0.001) (Table S4a).
For the MADRS, signiﬁcant main effects were observed for
response (F1,68,573= 6.155, p= 0.016); measurement day (F4,87,373
= 49.388, p < 0.001); measurement day × response interaction
(F4,87.492= 5.339, p= 0.001); and season (F3,61.090= 3.854, p=
0.014). MADRS scores signiﬁcantly decreased on all measurement
days compared with baseline (all p < 0.001) (Fig. 4a, Table S4b).
The interaction term revealed signiﬁcantly lower scores in
responders than non-responders on Days 4 (t= 4.242,
df= 83.491, p < 0.001); 10 (t= 2.394, df= 80.704, p= 0.019); and
31(t= 2.767, df= 55.519, p= 0.008), but not Day 17 (t= 1.169, df
= 81.646, p= 0.246). MADRS scores were signiﬁcantly higher in
spring than during other seasons (vs. summer p= 0.013; autumn
p= 0.020; winter p= 0.002). No signiﬁcant effects of sex (p=
0.420), age (p= 0.519), AaO (p= 0.855), FH (p= 0.784), or
diagnosis (p= 0.850) or MDD-PRS (p= 0.155) were observed.
For BDI-II, signiﬁcant main effects were observed for measurement
day (F4,65.719= 13.140, p<0.001), season (F3,57.224= 9.733, p<0.001)
and sex (F1,56.431= 5.091, p= 0.028). BDI-II scores decreased signiﬁ-
cantly on all measurement days compared with baseline (all
p<0.001) (Fig. 4b, Table S4c) and signiﬁcantly higher in spring
compared with all other seasons (all p< 0.001). No signiﬁcant
interaction between response ×measurement day was observed
(F4,65.719= 65.719, p= 0.296, trend for higher scores in non-
responders on Day 31, p= 0.085). Higher BDI-II scores were observed
in women (t= 2.256, df= 56.431, p= 0.28). No signiﬁcant effects of
response (p= 0.918), age (p= 0.960), AaO (p= 0.941), FH (p= 0.566),
or diagnosis (p= 0.712) or MDD-PRS (p= 0.559) were observed.
DISCUSSION
The observed association between response and both younger age
at presentation [17, 19] and higher age at disease onset [20]
replicate previous reports. The ﬁnding that responders and non-
responders did not differ in terms of baseline depressive symptom
scores is consistent with reports of depression severity not
inﬂuencing SD response [11, 17, 19, 42]. Previously reported
associations with diurnal variation were not observed [8–10].
Fig. 4 Post-treatment trajectories of a MADRS and b BDI-II scores. Error bars denote 95% conﬁdence intervals. BDI-II= Beck Depression
Inventory-II; MADRS=Montgomery-Åsberg Depression Rating Scale
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In the present cohort, the proportion of response to SD was on
the higher end of the range reported in a recent meta-analysis, in
which response rates ranged from 7 to 78% [5]. The authors
hypothesized that the small individual sample sizes were likely to
contribute to this wide range of response rates. It is of note that
the mean sample size of these studies was ~ 23 and ~ 66% of
these studies had smaller sample sizes. In the present study, we
applied the same protocol consistently in a large sample of
patients over a protracted period of time, making the response
rate we observed more robust and less prone to spurious factors
which might be observed in small samples assessed during
relatively short time spans.
We examined genetic burden for MDD using PRS, ﬁnding
signiﬁcantly higher scores in non-responders than controls. We
also found higher PRS in non-responders compared to responders,
although differences were not statistically signiﬁcant. These
preliminary data suggest that underlying biological differences
may be involved in SD effects and may suggest an avenue for
exploration in larger samples. Although initial depression severity
did not differ in responders and non-responders, differing
subjective mood and mood trajectories were observed. Better
baseline mood in responders may indicate better attitude towards
the treatment, and should be further explored. Interestingly, both
responders and non-responders experienced some degree of
mood improvement during SD; although the interaction between
response and timepoint was not statistically signiﬁcant (Fig. 3a,
S1), this might be qualitatively accounted for by mood scores in
responders in crossing the mid-point of the VAS (i.e., from the
‘negative’ to ‘positive’ side of the scale). Further research should
use multi-dimensional mood assessments to better examine the
changes.
We found no evidence of differing baseline mood/mood
trajectories between unipolar and bipolar patients. Nevertheless,
care should be taken when assessing mood in bipolar patients, as
deﬁnitions of “better” mood may differ from unipolar patients if
referencing a previous manic/hypomanic episode, leading to
potential bias.
Tiredness levels, previously reported to predict response [12],
did not differ between responders and non-responders; except for
in the early evening (see supplementary text, Figure S2)
trajectories were similar in all participants.
Correlations observed between BDI-II/MADRS suggest validity of
both scales. Although trajectories appeared similar, the interaction
between response and assessment day was signiﬁcant for MADRS,
but not BDI-II. This may be attributable to (1) differences in number of
items and points assigned to each item and (2) the fact that the BDI-II
is a subjective measure, containing many items assessing maladaptive
personality traits [43] unlikely to change in the short-term. Interest-
ingly, women reported higher BDI-II but not MADRS scores than men,
which may further suggest that the symptoms contributing to
depression are different between the sexes.
Importantly, these longitudinal scores reﬂect clinical treatment
outcomes, suggesting that response to SD may be a general indicator
of response to further treatment. We included season to control for
possible effects (daylight hours, temperature), ﬁnding more pro-
nounced depressive symptoms in the spring, which is consistent with
previous research showing exacerbation of mood disorders in spring
[44]. We note that whereas the BDI-II and MADRS detected no
baseline differences between groups, the VAS did. The VAS measures
positive mood, which is not assessed in depressive symptom scales.
This suggests that future studies should quantify positive mood, and
as mentioned above, that measurement of the multiple dimensions of
mood/affect would allow more rigorous characterization of beha-
vioural patterns during SD.
This study had several limitations. First, as this was a naturalistic
study, patients were not randomised/stratiﬁed with respect to
medication, diagnoses, age at onset, or illness duration. Second,
the sample size was too small to control for all potential
inﬂuences, despite being one of the larger reported SD cohorts
to date. Third, response to SD was assessed using the CGIC, which
does not allow speciﬁcation of which symptoms have changed.
However, changes in both the MADRS and BDI-II scores were
consistent with the CGIC. Fourth, for the tiredness measure,
participants were not given further instruction beyond that given
in the questionnaire to differentiate ‘sleepiness’ from the ‘general
fatigue’ characterizing depression, and caution is needed when
interpreting this ﬁnding. Fifth, comparison with depressed
patients not undergoing SD would have strengthened the
interpretation of our ﬁndings. Finally, we did not correct p values
for multiple testing.
In conclusion, the rapid, pronounced effects of SD render it a
well-controlled, efﬁcient model [45]. We propose that it is a
promising context to apply targeted investigation of abnormal
clock gene expression related to MDD and SD in humans [46] and
animal models [47], novel methods such as genome-wide analyses
(of the epi/genome and proteome) [22, 48–53], and furthermore
ecologically valid techniques such as ambulatory assessment [54].
We believe that such an approach is suitable to not only link
observed phenotypic changes with underlying biological factors,
but to do so in a way such that depression heterogeneity (and
interindividual differences) can be dissected.
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